• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>International Journal of Preventive Medicine >BRIEF COMMUNICATION: COMMENTARY ON PREVENTION A POSSIBLE DRUG–DRUG INTERACTION: IS CONCURRENT ADMINISTRATION OF ORLISTAT AND PIOGLITAZONE INCREASE THE RISK OF DURG?INDUCED HEPATOTOXICITY?
【24h】

BRIEF COMMUNICATION: COMMENTARY ON PREVENTION A POSSIBLE DRUG–DRUG INTERACTION: IS CONCURRENT ADMINISTRATION OF ORLISTAT AND PIOGLITAZONE INCREASE THE RISK OF DURG?INDUCED HEPATOTOXICITY?

机译：简要通信：预防药物-药物相互作用的评论：持续服用奥利司他和吡格列酮是否增加了杜格的风险？引起的肝毒性吗？

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Background: Drug–drug interactions (DDIs) are an emerging threat to public health and are difficult to detect. To prevent DDIs and their burden, the possible DDIs should be kept in mind. We know that the obesity predisposes to the development of insulin resistance and type 2 diabetes. Therefore, combinational uses of antiobesity drugs and glucose ? lowering drugs are very common. As the hepatotoxicity of both pioglitazone (an antidiabetic drug) and orlistat (an antiobesity drug) has been shown in some cases, the aim of this study was to evaluate the interaction of pioglitazone and orlistat in human hepatocellular cell line human hepatocellular carcinoma (HepG2) cells to determine their effect on liver toxicity.Methods: Human hepatocellular carcinoma cells were treated with 25 m M Pioglitazon (Pio), 20 m M Orlistat (Orl) pioglitazone, orlistat or combination of them. The MTT assay was used to assess cell viability.Results: Pioglitazone and orlistat combination caused a loss of HepG2 cell viability. While pioglitazone (25 m M) and orliatat (20 m M) alone decreased the cell viability around 91% and 85% respectively (notsignificant, P>0.05), the combination of these two drugs reduced the amount of viable cells to 55% which was significant when compared with each drug alone (PConclusions: Revealing the significant loss of viability of HepG2 cells in the combination use of pioglitazone and orlistat indicates these two drugs should not be administered at the same time to prevent their hepatotoxic effects especially in patients with liver dysfunction.
机译：背景：药物相互作用（DDI）是对公共卫生的新兴威胁，难以发现。为了防止DDI及其负担，应牢记可能的DDI。我们知道，肥胖易患胰岛素抵抗和2型糖尿病。因此，减肥药和葡萄糖的联合使用？降低药物非常普遍。由于在某些情况下已经显示了吡格列酮（抗糖尿病药）和奥利司他（抗肥胖药）的肝毒性，本研究的目的是评估吡格列酮和奥利司他在人肝细胞系人肝细胞癌（HepG2）中的相互作用。方法：用25 m M吡格列酮（Pio），20 m M奥利司他（Orl）吡格列酮，奥利司他或它们的组合处理人肝癌细胞。结果：吡格列酮和奥利司他联合导致HepG2细胞活力丧失。吡格列酮（25 m M）和奥里亚特（20 m M）单独将细胞活力分别降低了约91％和85％（无统计学意义，P> 0.05），而这两种药物的组合将存活细胞数量降低至55％与单独使用每种药物比较时具有显着意义（PConclusions：揭示吡格列酮和奥利司他组合使用时HepG2细胞活力的显着降低表明这两种药物不应同时给药以防止其肝毒性作用，尤其是在肝癌患者中）功能障碍。

著录项

相似文献

  • 外文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号